Logo image of PETS

PETMED EXPRESS INC (PETS) Stock Fundamental Analysis

NASDAQ:PETS - Nasdaq - US7163821066 - Common Stock - Currency: USD

4.5  -0.77 (-14.61%)

Fundamental Rating

4

PETS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 120 industry peers in the Specialty Retail industry. While PETS has a great health rating, there are worries on its profitability. While showing a medium growth rate, PETS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

PETS had positive earnings in the past year.
In the past year PETS had a positive cash flow from operations.
PETS had positive earnings in 4 of the past 5 years.
PETS had a positive operating cash flow in each of the past 5 years.
PETS Yearly Net Income VS EBIT VS OCF VS FCFPETS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

1.2 Ratios

PETS has a Return On Assets (-0.66%) which is comparable to the rest of the industry.
PETS's Return On Equity of -1.00% is in line compared to the rest of the industry. PETS outperforms 51.28% of its industry peers.
Industry RankSector Rank
ROA -0.66%
ROE -1%
ROIC N/A
ROA(3y)2.57%
ROA(5y)8.14%
ROE(3y)2.43%
ROE(5y)9.77%
ROIC(3y)N/A
ROIC(5y)N/A
PETS Yearly ROA, ROE, ROICPETS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

With a Gross Margin value of 27.51%, PETS is not doing good in the industry: 71.79% of the companies in the same industry are doing better.
PETS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for PETS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-3.61%
PETS Yearly Profit, Operating, Gross MarginsPETS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

7

2. Health

2.1 Basic Checks

PETS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PETS has more shares outstanding
The number of shares outstanding for PETS has been increased compared to 5 years ago.
There is no outstanding debt for PETS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PETS Yearly Shares OutstandingPETS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
PETS Yearly Total Debt VS Total AssetsPETS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 4.00 indicates that PETS is not in any danger for bankruptcy at the moment.
The Altman-Z score of PETS (4.00) is better than 81.20% of its industry peers.
PETS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4
ROIC/WACCN/A
WACC10.38%
PETS Yearly LT Debt VS Equity VS FCFPETS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.45 indicates that PETS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.45, PETS is in line with its industry, outperforming 55.56% of the companies in the same industry.
PETS has a Quick Ratio of 1.18. This is a normal value and indicates that PETS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.18, PETS is in the better half of the industry, outperforming 79.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.45
Quick Ratio 1.18
PETS Yearly Current Assets VS Current LiabilitesPETS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 102.56% over the past year.
The Revenue has grown by 9.41% in the past year. This is quite good.
The Revenue has been decreasing by -0.17% on average over the past years.
EPS 1Y (TTM)102.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)9.41%
Revenue growth 3Y-3.13%
Revenue growth 5Y-0.17%
Sales Q2Q%-18.89%

3.2 Future

Based on estimates for the next years, PETS will show a very strong growth in Earnings Per Share. The EPS will grow by 31.76% on average per year.
PETS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.08% yearly.
EPS Next Y144.46%
EPS Next 2Y38.15%
EPS Next 3Y31.76%
EPS Next 5YN/A
Revenue Next Year-7.88%
Revenue Next 2Y-2.42%
Revenue Next 3Y1.08%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PETS Yearly Revenue VS EstimatesPETS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
PETS Yearly EPS VS EstimatesPETS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 450.00, which means the current valuation is very expensive for PETS.
The rest of the industry has a similar Price/Earnings ratio as PETS.
PETS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.20.
PETS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 450
Fwd PE N/A
PETS Price Earnings VS Forward Price EarningsPETS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100 200 300 400

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PETS is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.95
PETS Per share dataPETS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PETS does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as PETS's earnings are expected to grow with 31.76% in the coming years.
PEG (NY)3.12
PEG (5Y)N/A
EPS Next 2Y38.15%
EPS Next 3Y31.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PETS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PETMED EXPRESS INC

NASDAQ:PETS (2/11/2025, 11:38:08 AM)

4.5

-0.77 (-14.61%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)02-10 2025-02-10/amc
Earnings (Next)N/A N/A
Inst Owners61.15%
Inst Owner Change-36.77%
Ins Owners4.77%
Ins Owner Change14.04%
Market Cap92.97M
Analysts42.86
Price Target3.83 (-14.89%)
Short Float %8%
Short Ratio5.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.59
Dividend Growth(5Y)-11.13%
DP-22.01%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)296.08%
Min EPS beat(2)296.08%
Max EPS beat(2)296.08%
EPS beat(4)2
Avg EPS beat(4)-134.59%
Min EPS beat(4)-880.39%
Max EPS beat(4)296.08%
EPS beat(8)3
Avg EPS beat(8)-121.4%
EPS beat(12)4
Avg EPS beat(12)-90.48%
EPS beat(16)4
Avg EPS beat(16)-71.39%
Revenue beat(2)0
Avg Revenue beat(2)-11.34%
Min Revenue beat(2)-11.51%
Max Revenue beat(2)-11.17%
Revenue beat(4)1
Avg Revenue beat(4)-5.97%
Min Revenue beat(4)-11.51%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-6.2%
Revenue beat(12)1
Avg Revenue beat(12)-6.34%
Revenue beat(16)2
Avg Revenue beat(16)-6.07%
PT rev (1m)0%
PT rev (3m)7.14%
EPS NQ rev (1m)50%
EPS NQ rev (3m)50%
EPS NY rev (1m)0%
EPS NY rev (3m)100%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 450
Fwd PE N/A
P/S 0.36
P/FCF N/A
P/OCF 27.27
P/B 0.96
P/tB 1.71
EV/EBITDA 9.95
EPS(TTM)0.01
EY0.22%
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)0.17
OCFY3.67%
SpS12.55
BVpS4.67
TBVpS2.63
PEG (NY)3.12
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.66%
ROE -1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.51%
FCFM N/A
ROA(3y)2.57%
ROA(5y)8.14%
ROE(3y)2.43%
ROE(5y)9.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-3.61%
F-Score5
Asset Turnover1.78
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 61.31%
Cap/Sales 1.67%
Interest Coverage N/A
Cash Conversion 59.7%
Profit Quality N/A
Current Ratio 1.45
Quick Ratio 1.18
Altman-Z 4
F-Score5
WACC10.38%
ROIC/WACCN/A
Cap/Depr(3y)91.99%
Cap/Depr(5y)95.64%
Cap/Sales(3y)1.43%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y144.46%
EPS Next 2Y38.15%
EPS Next 3Y31.76%
EPS Next 5YN/A
Revenue 1Y (TTM)9.41%
Revenue growth 3Y-3.13%
Revenue growth 5Y-0.17%
Sales Q2Q%-18.89%
Revenue Next Year-7.88%
Revenue Next 2Y-2.42%
Revenue Next 3Y1.08%
Revenue Next 5YN/A
EBIT growth 1Y87.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year174.21%
EBIT Next 3Y64.55%
EBIT Next 5YN/A
FCF growth 1Y-104.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-84.87%
OCF growth 3Y-52.42%
OCF growth 5Y-37.46%